We are a new biotechnology company with large DNA-encoded libraries of extremely drug-like compounds (n =660 million compounds so far). DNA-encoding allows for rapid synthesis and efficient screening. We have developed and used our screening capability to deliver high-quality chemical matter to our corporate partners. We have now begun our first in-house drug-discovery program.